| 摘要: |
| 本文对2019年美国食品药品监督管理局(FDA)批准的新药进行了统计分析,通过对新药和孤儿药基本情况、获得优先审批权、临床病例数等进行对比分析,详细了解美国食品药品监督管理局对新药孤儿药的审批优惠政策,提出我国制定孤儿药相关政策的建议,为我国相关政策的制定和企业相关产品研发工作提供思路。 |
| 关键词: 美国食品药品监督管理局批准新药 孤儿药 优先审批权 病例数 |
| DOI:10.13506/j.cnki.jpr.2020.09.013 |
| 基金项目: |
|
|
|
| Analysis of the orphan drug approvals of FDA in 2019 |
| ZHOU Chong,LIU Juntian,XIAO Jie |
| (Shandong Center for Food and Drug Evaluation&Certification,Jinan 250014,China) |
| Abstract: |
| This paper analyzed statistic all of the new drug approved by FDA in 2019. Emphasizing on analyzing the difference of the basic information, priority for approval, clinical number of orphan drugs and new drugs, to understand the priority for orphan drug approvals. Some suggestions are put forward on the orphan drug policy in China,providing references for the establishment of orphan drug policies and research in our country. |
| Key words: New drug approved by FDA Orphan drug Priority for approval Clinical number |